Radiation Oncology

Breast Cancer, Metastatic

Questions discussed in this category

What are your top takeaways in Breast Cancer from ESMO 2024?

What are your top takeaways in Breast Cancer from ASTRO 2024?

How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?

1 Answer available

In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?

3 Answers available

Can trastuzumab deruxtecan be continued during radiation?

The patient has extensive disease, and requires palliative radiation to the scapular area (proximal to the brachial plexus) in a region overlapping wi...

1 Answer available

Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?

Any pitfalls to be aware of?

1 Answer available

Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?

8 Answers available

In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?

3 Answers available

What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?

Is there a role for loco-regional treatment in this scenario? If a young patient with ER/PR positive cT2N2M1 IDC presents with a single bone metastasi...

1 Answer available

How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?

Controlled extracranial disease on trastuzumab+pertuzumab for 2 years. Treatment options include Enhertu or WBRT. Not a candidate for SRS or neurosurg...

1 Answer available

What are your top takeaways from SABCS 2023?

4 Answers available

What are your top takeaways in Breast Cancer from ASCO 2023?

4 Answers available

How would you treat bilateral synchronous breast cancer with single bony metastatic disease on imaging when one is ER+ HER2 neg and other is TNBC?

1 Answer available

Would you give palliative breast RT to a patient receiving weekly paclitaxel for rapidly progressing metastatic disease?

If a patient has a painful breast lesion in the setting of rapidly progressing systemic disease treated with weekly taxol (60 mg/m2), would you feel c...

3 Answers available

What are your top takeaways in Breast Cancer from ASCO 2022?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

12 Answers available

For a young patient who had a prior pCR to neoadjuvant therapy, would you consider systemic therapy after local resection and radiation of an isolated brain metastatic recurrence of triple negative breast cancer?

CNS recurrence occurred within two years of prior neoadjuvant therapy

1 Answer available

Do you hold palbociclib (or another CDK4/6 inhibitor) in a patient with metastatic HR+ breast cancer while receiving palliative radiation?

4 Answers available

Papers discussed in this category

Radiother Oncol, 2017 Sep 27

Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med,

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

N Engl J Med, 2022 Jun 05

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

J Natl Compr Canc Netw, 2021 Mar 24

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.

N Engl J Med,

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

International journal of radiation oncology, biology, physics, 2012-04-01

High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

J Clin Oncol, 2022 Jan 07

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).

J Am Coll Surg, 2021 Sep 13

Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

N Engl J Med, 2015 Jul 23

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Breast Cancer Res Treat, 2009 Jun

Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.

Annals of surgical oncology, 2018-10

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.

The Journal of community and supportive oncology, 2014-10

Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis.

Journal of the National Cancer Institute, 1996-10-16

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

The oncologist, 2019-03

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Breast cancer research and treatment, 2019-04

Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.

Ann Surg,

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020 Apr 22

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.

Annals of oncology : official journal of the European Society for Medical Oncology, 2020 Sep 23

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of surgical oncology, 2020 Oct 30

Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status.

JAMA oncology, 2021 Jan 01

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology, 2021 Oct 19

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 26

Impact of F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2020 Sep

Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.

Radiology, 2012 Dec 06

Performance of FDG PET/CT in the clinical management of breast cancer.

Nat Med, 2022 Aug 08

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Aug 21

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

The Lancet. Oncology, 2014-02

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

JAMA Oncol, 2020 Aug 13

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

Clinical chemistry, 2020 Nov 01

Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification.

British journal of cancer, 1987 Jan

The clinical course of bone metastases from breast cancer.

The oncologist, 2013 May 30

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

The American journal of surgical pathology, 2019 Oct

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023 Jul 10

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.

Cancers, 2022 Jan 08

Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series.

Cancers, 2023 Apr 13

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence.

Nature reviews. Clinical oncology, 2021 Feb 08

Unlocking the potential of antibody-drug conjugates for cancer therapy.

JAMA oncology, 2023 Dec 01

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Breast cancer research : BCR, 2020 Nov 30

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.

The New England journal of medicine, 2024 Sep 15

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Nature medicine, 2024 Sep 13

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

The New England journal of medicine, 2024 Sep 15

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

BMJ Open, 2019 Oct 15

Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.

J Clin Oncol, 2020 Jul 30

Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.

JAMA oncology, 2024 Oct 01

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.

Lancet Oncol., 2019 Jan 30

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.

Radiation Oncology

Breast Cancer, Metastatic

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology